CALT | Jotup

Calliditas Therapeutics to Attend Investor Conferences in March

Retrieved on:

Friday, March 1, 2024

STOCKHOLM, March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.

Key Points:

STOCKHOLM, March 1, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.
Carnegie Healthcare Seminar, Wednesday, March 6, 2024.
Fireside chat will be held at 10:20 - 10:50 am CET and one-on-one meetings will be available.
Jefferies Biotech on the Bay Summit, Wednesday, March 13, 2024 in Miami, FL, one-on-one meetings will be available.

Calliditas provides patent update

Retrieved on:

Tuesday, February 13, 2024

Orange Book, Sustainability, Capsule, Person, Budesonide, Patent, CALT, Immunoglobulin A, IgA nephropathy, The Orange Book

STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no.

Key Points:

STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no.
This is Calliditas' second patent for TARPEYO in the United States, and provides product protection until 2043.
The patent covers a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name "NEFECON®".
Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.

Calliditas provides patent update

Retrieved on:

Tuesday, February 13, 2024

Orange Book, Sustainability, Capsule, Person, Budesonide, Patent, CALT, Immunoglobulin A, IgA nephropathy, The Orange Book

STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no.

Key Points:

STOCKHOLM, Feb. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no.
This is Calliditas' second patent for TARPEYO in the United States, and provides product protection until 2043.
The patent covers a method of treating IgA nephropathy with a composition that encompasses TARPEYO® (budesonide) delayed release capsules, developed under the name "NEFECON®".
Calliditas intends to file corresponding patent applications in additional territories around the world, including Europe and China.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on:

Sunday, January 7, 2024

NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points:

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
"We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas Therapeutics appoints Maria Törnsén as President North America

Retrieved on:

Sunday, January 7, 2024

NOX, Immunoglobulin A, Risk, FDA, Sustainability, Capsule, Person, Sarepta Therapeutics, Therapy, IgA nephropathy, Growth, SVP, Patient, CALT, Pharmaceutical industry

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.

Key Points:

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America.
Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles.
Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics.
"We are pleased to welcome Ms Törnsén to the executive management team as President of our US operations.

Calliditas to present at JP Morgan Healthcare Conference

Retrieved on:

Sunday, January 7, 2024

Sustainability, Conference, CALT

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.

Key Points:

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.
Calliditas will present an update on the company at 7:30 am PT on Tuesday 9th January.
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.
: +46 76 403 35 43, Email: [email protected]
The information was sent for publication, through the agency of the contact person set out above, on January 7, 2024 at 3:00 p.m. CET.

Calliditas to present at JP Morgan Healthcare Conference

Retrieved on:

Sunday, January 7, 2024

Sustainability, Conference, CALT

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.

Key Points:

STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California.
Calliditas will present an update on the company at 7:30 am PT on Tuesday 9th January.
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.
: +46 76 403 35 43, Email: [email protected]
The information was sent for publication, through the agency of the contact person set out above, on January 7, 2024 at 3:00 p.m. CET.

Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital

Retrieved on:

Wednesday, December 27, 2023

FDA, Sustainability, Person, Athyrium, Patent, CALT, Security (finance)

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium").

Key Points:

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium").
Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital.
The principal amount of the new loan is 24 million Euros greater than that of the prior facility.
"Signing this four-year term loan facility ensures an extension and expansion of our access to significant non-dilutive capital.

Calliditas refinances existing term loan with Euro 92 million senior secured facility with Athyrium Capital

Retrieved on:

Wednesday, December 27, 2023

FDA, Sustainability, Person, Athyrium, Patent, CALT, Security (finance)

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium").

Key Points:

STOCKHOLM, Dec. 27, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium").
Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital.
The principal amount of the new loan is 24 million Euros greater than that of the prior facility.
"Signing this four-year term loan facility ensures an extension and expansion of our access to significant non-dilutive capital.

Everest Medicines' Partner Calliditas Therapeutics Announces Nefecon® the Only FDA-approved Treatment for IgA Nephropathy to Significantly Slow Kidney Function Decline

Retrieved on:

Thursday, December 21, 2023

Mount Everest, IgA nephropathy, FDA, HKEX, Capsule, Food, Risk, Proteinuria, CALT

Nefecon® was first approved in December 2021 under the FDA accelerated approval pathway and is now the first fully FDA-approved treatment for IgAN based on a measure of kidney function.

Key Points:

Nefecon® was first approved in December 2021 under the FDA accelerated approval pathway and is now the first fully FDA-approved treatment for IgAN based on a measure of kidney function.
The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels.
Results from Chinese subpopulation analysis demonstrated a numerically greater magnitude of Nefecon® treatment effect over placebo in kidney function, proteinuria and microhematuria compared to the global population.
"We congratulate our partner on the full FDA approval of Nefecon®, which confirms the drug's capability to preserve kidney function and significantly delay disease progression.